×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Improving Returns on Invested Capital in the Pharmaceutical and Biotechnology Industry
Session Chair(s)
Akhil Agrawal, MD, PMP
Associate Director
Bristol-Myers Squibb Company, United States
This session will focus on sharing best practices when adapting to the changing health care environment and improving the value of R&D projects. Presentations including case studies will be provided followed by an open forum discussion.
Learning Objective : Discuss how to adapt to changing circumstances to improve the return on invested capital (ROIC) for R&D projects; Describe broader trends such as the changing health care environment, more influential small biotech (including virtual firms) and CROs, and importance of global strategies.
Speaker(s)
Early Commercialization: It’s More Than Just Early Input from Marketing
Alan C. Crowther
Alliance Life Sciences, United States
Chief Executive Officer
Key Cost Drivers in Clinical Trials
Frank J. Cattie
Medidata Solutions, United States
Vice President, Trial Planning Solutions
Maximizing the Value of Licensed Drug: Blending Science with Commercial Assessment and Contemporary Funding Models
Richard Williams, JD, PhD
Covance Inc., United States
Regulatory Strategy
Have an account?